Cost–consequence analysis of 18F-fluciclovine for the staging of recurrent prostate cancer

Cost–consequence analysis of 18F-fluciclovine for the staging of recurrent prostate cancer

Background: Current detection methodologies are often unable to identify the location and extent of recurrent prostate cancer (PCa) leading potentially to ‘futile’ local therapies in the presence of metastatic disease. The use of 18 F-fluciclovine PET/CT may lead to better patient management. Object...

Full description

Bibliographic Details
Main Authors: Ivar S Jensen, Joanne Hathway, Philip Cyr, David Gauden, Peter Gardiner
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:Journal of Market Access & Health Policy
Subjects:
18f-fluciclovine
prostate cancer
recurrence
diagnostic imaging
budget impact
cost-consequence
Online Access:http://dx.doi.org/10.1080/20016689.2020.1749362

Similar Items

Similar Items